Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?

  • Aysun Şentürk YikilmazEmail author
  • Sema Akinci
  • Şule Mine Bakanay
  • Zeynep Büşra Zengin
  • İmdat Dilek
Original Article


Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive disease (Group 2). Group 1 included those who did not require any treatment since diagnosis and those who did not progress after receiving the first step anti CLL treatment. Group 2 included the patients who received ≥ 2 steps treatment. The relation between the two groups was analyzed statistically in terms of clinical, laboratory and flow cytometric findings. Twenty patients (36.3%) required treatment at the time of diagnosis, four patients (3.8%) received first-line treatment during follow-up and 31 (56.3%) patients were followed without any treatment. Thirteen patients required second step treatment after a median of 26.3 months. The risk of progression was found to be increased 5-fold (p = 0.015) in the CD38 positive patient group, 4.2-fold (p = 0.0147) in the FMC7 negative patient group and 2.8-fold in the CD11c negative patient group. FMC 7 negativity decreased total survival 5.9-fold (p = 0.051). Unlike similar publications, we found that patients with CD11c or FMC7 negativity were in a higher need for ≥ 2 step treatment. This suggests that CD11c or FMC7 negativity may be used as a poor prognostic marker in CLL.


CLL Flowcytometry FMC7 CD11c 



The authors declared that this study has received no financial support.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105:1684–1692. CrossRefGoogle Scholar
  2. 2.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219Google Scholar
  3. 3.
    Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1):198CrossRefGoogle Scholar
  4. 4.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2008) International workshop on chronic lymphocytic leukemia, guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446CrossRefGoogle Scholar
  5. 5.
    Diehl LF, Ketchum LH (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25(1):80Google Scholar
  6. 6.
    Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5):956CrossRefGoogle Scholar
  7. 7.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, LyonGoogle Scholar
  8. 8.
    Rai KR, Montserrat E (1987) Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 24(4):252–256Google Scholar
  9. 9.
    Molica S, Alberti A (1987) Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 60(11):2712CrossRefGoogle Scholar
  10. 10.
    Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62(3):567CrossRefGoogle Scholar
  11. 11.
    Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526(7574):525–530CrossRefGoogle Scholar
  12. 12.
    Gentile M, Mauro FR, Rossi D, Vincelli I, Tripepi G, Recchia AG et al (2014) Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 167(2):224–232CrossRefGoogle Scholar
  13. 13.
    Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA et al (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679CrossRefGoogle Scholar
  14. 14.
    Mina A, Sandoval Sus J, Sleiman E, Pinilla-Ibarz J, Awan FT, Kharfan-Dabaja MA (2017) Using prognostic models in CLL to personalize approach to clinical care: are we there yet? Blood Rev. Google Scholar
  15. 15.
    Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840Google Scholar
  16. 16.
    Dürig J, Nückel H, Cremer M, Führer A, Halfmeyer K, Fandrey J et al (2003) ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17(12):2426CrossRefGoogle Scholar
  17. 17.
    Moreno C, Montserrat E (2008) New prognostic markers in chronic lymphocytic leukemia. Blood Rev 22:211–219CrossRefGoogle Scholar
  18. 18.
    Delgado J, Matutes E, Morilla AM, Morilla RM, Owusu-Ankomah KA et al (2003) Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. FMedSci. Google Scholar
  19. 19.
    Wormsley SB, Baird SM, Gadol N, Rai KR, Sobol RE (1990) Characteristics of CD1 lc + CDS + chronic B-cell leukemias and the identification of novel peripheral blood b-cell subsets with chronic lymphoid leukemia ımmunophenotypes. Blood 76:123–130Google Scholar
  20. 20.
    Pinilla-Ibarz J, Emole J (2015) Chronic lymphocytic leukemia in the elderly, which investigations are necessary: a map for the practicing oncologist. Cancer Control 22(4 Suppl):7–16CrossRefGoogle Scholar
  21. 21.
    Hamed NAM (2017) Treatment of chronic lymphocytic leukemia in the elderly, Alexandria University, Egypt Submission 10 Mar 2017; Published: 16 Mar 2017Google Scholar
  22. 22.
    Balducci L, Dolan D (2015) Chronic lymphocytic leukemia in the elderly: epidemiology and proposed patient-related approach. Cancer Control 22(4 Suppl):3–6CrossRefGoogle Scholar
  23. 23.
    Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW et al (1987) Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47(3):830Google Scholar
  24. 24.
    Postigo AA, Corbi AL, Sanche-Madrid F, Landazuri MO (1991) Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18. J Exp Med 174(12):1313–1322CrossRefGoogle Scholar
  25. 25.
    Sivakumaran S, Henderson S, Ward S, Sousa PS, Manzo T, Zhang L et al (2016) Depletion of CD11c+ cells in the CD11c.DTR model drives expansion of unique CD64+ Ly6C+ monocytes that are poised to release TNF-α. Eur J Immunol 46(1):192–203. CrossRefGoogle Scholar
  26. 26.
    Umit EG, Baysal M, Durmus Y, Demir AM (2017) CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival. Int J Lab Hematol 39(5):552–556. CrossRefGoogle Scholar
  27. 27.
    Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M et al (2015) ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(5):78–84. CrossRefGoogle Scholar
  28. 28.
    Reddy P, Dabbas B, Gama M, Kocher T, Drum H, Taylor J et al (2012) FMC-7 expression identifies phenotypically atypical chronic lymphocytic leukemia with distinct clinical and molecular genetic features. Blood 120(21):2478Google Scholar
  29. 29.
    Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M (1990) Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 76(3):352–358CrossRefGoogle Scholar
  30. 30.
    Mainou-Fowler T, Dignum H, Taylor PR, Dickinson AM, Saunders PW, Proctor SJ et al (2002) Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol 118(3):755CrossRefGoogle Scholar
  31. 31.
    Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD et al (2007) ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 13(18 Pt 1):5295CrossRefGoogle Scholar
  32. 32.
    Meyerson HJ, Dalia SM, Koc ON, Fu P, Cocco AE (2004) Cellular expression of CD23, CD71, and CD38 are ındependent prognostic variables in B-cell chronic lymphocytic leukemia. Blood 104(11):47–5313Google Scholar
  33. 33.
    D’Arena G, Musto P, Cascavilla N, Dell’Olio M, Di Renzo N, Perla G et al (2001) CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 42(1–2):109CrossRefGoogle Scholar
  34. 34.
    Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A et al (2002) CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 16(1):30CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2019

Authors and Affiliations

  1. 1.Department of HematologyYildirim Beyazit UniversityAnkaraTurkey
  2. 2.Department of HematologyAtaturk Training and Research HospitalAnkaraTurkey

Personalised recommendations